Abu Dhabi fighting cancer with new hi-tech facility and 90% cheaper treatment

Abu Dhabi is set to play host to the Middle East's first heavy ion cancer therapy facility, of which only 15 exist in the world, while locally manufactured cell antigen treatments could cut costs by up to 90 per cent. Carbon ion therapy is an advanced form of radiotherapy that delivers high-energy particles with exceptional precision, offering new hope to patients with tumours that do not respond to conventional treatments. The technology is known for its ability to minimise damage to healthy tissue while aggressively targeting cancer cells. Construction of the facility, which will be located at the Sheikha Fatima bint Mubarak Centre at Cleveland Clinic Abu Dhabi, is expected to begin in 2026. It will be the only one within a five-hour flight from the emirate when it opens, according to Hassan Al Nowais, managing director of M42, one of the health companies at the heart of the project. Local manufacturing and training, meanwhile, to carry out chimeric antigen receptor (Car) T-cell therapy is set to cut treatment costs by up to 90 per cent, according to Burjeel Holdings, who announced a partnership with US-based non-profit Caring Cross at Abu Dhabi Global Health Week on Tuesday. Car T-cell therapy is a type of immunotherapy that collects a patient's blood, isolates their T-cells – specialised immune cells – modifies them in a lab so they can recognise and attack cancer, and then reinfuses them back into the patient, essentially reprogramming the immune system to become a personalised weapon against cancer. It is currently one of the most expensive forms of cancer treatment available – the cost of one treatment cycle in the US can exceed $1.5 million. The heavy ion cancer therapy facility will be made possible through a partnership between M42, Cleveland Clinic Abu Dhabi, and Japan's Toshiba Energy Systems and Solutions. 'It's definitely something transformational for Abu Dhabi. It's a project I've been working on for at least the last seven years,' Mr Al Nowais told The National. 'Only 15 of these devices exist globally, mainly in Japan, Korea and Germany, and this will be the only one within a five-hour flight from Abu Dhabi. It will bring the best treatments to our patients here and will begin to attract patients from across the region. It will save lives, especially for those where traditional therapies no longer work.' Dr Stephen Grobmyer, director of the oncology institute at Cleveland Clinic Abu Dhabi, said heavy ion therapy is a powerful form of radiation that uses charged particles to deliver significantly more energy to tumours than traditional radiotherapy. 'In some cancers, like specific types of lung cancer, a single session [of heavy ion therapy] may replace weeks of treatment. It allows us to treat patients who previously had no hope from radiation at all.' Cleveland Clinic Abu Dhabi has already started specialised training for the medical, technical and engineering teams who will run the facility. The hospital has also signed agreements with Japan's Quantum Science and Technology Hospital, and additional agreements with other leading Japanese institutions are expected in the coming weeks. On Car T-cell therapies, Burjeel Holdings will work with Caring Cross to bring the necessary technology, materials, and specialised training to Abu Dhabi for manufacturing. It is hoped doing this locally will slash costs dramatically, by up to 90 per cent. The treatment has shown remarkable success in the fight against blood cancers like leukaemia and lymphoma. The first phase of the programme will focus on Car T-cell therapies for these two forms of blood cancer, with plans to explore treatments for other diseases, including HIV, in the future. 'This is a monumental stride in enhancing access to cancer treatments and addressing the escalating need for advanced health care globally,' said Dr Ajlan Al Zaki, director of the hematology oncology and cellular therapy centre at Burjeel Hospital Abu Dhabi. In a previous interview with The National, Dr Al Zaki, who is the first and only Emirati doctor to specialise in cellular cancer therapy, said more widespread access to Car T-cell therapy is "the dream" as it could one day be offered to all before chemotherapy. Rather than shipping patient cells abroad for processing, Dr Al Zaki hopes to set up a lab in the UAE to perform the entire process domestically. In 2023, Abu Dhabi Stem Cell Centre (ADSCC), a subsidiary of Pure Health, successfully manufactured the UAE's first Car T-cells to treat an 11-year-old boy with leukaemia. 'It would be exciting to bring down the cost of Car T-cell therapy … or a collaborative opportunity in the UAE would be something very beneficial," he said. "The technology is out there, the knowledge is out there. If we do the programming ourselves, you already cut down the cost by several hundreds of thousands of dollars.' While Car T-cell therapy is currently used to treat blood cancers, researchers including Dr Zaki are exploring ways to expand its reach to solid tumours. He also wants to see the UAE become a centre for clinical trials and specialised expertise.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Web Release

9 hours ago

• Web Release

2ND INNINGS earns MA'AN certification, joins My Dubai Community App to empower seniors across the UAE

2ND INNINGS, a UAE-based startup dedicated to transforming the lives of elderly individuals, has been officially granted Ma'an certification from the Authority of Social Contribution and is listed on the My Dubai Community App. The Ma'an certification establishes the startup as a trusted, government-recognized social enterprise, enhancing its credibility with families, partners, and the wider community. As the UAE continues to invest in quality-of-life improvements across all age groups, 2ND INNINGS ensures that senior citizens are not left behind. Through an affordable, digital and in-person approach, the platform is making health, movement, and companionship accessible to all — no matter their age, ability, or income level. Moreover, being listed on the My Dubai Community App enhances visibility and accessibility, enabling more seniors and families across the UAE to benefit from the services offered by 2ND INNINGS. The certification also ensures that the organization operates in full compliance with UAE regulatory standards and aligns its mission with key national priorities, including the 'Year of Community 2025'. In addition, the mission and work of 2ND INNINGS contribute meaningfully to the UAE's commitment to achieving the 'United Nations Sustainable Development Goals (SDGs)'. The startup supports SDG 3: Good Health and Well-being through its wellness and fitness programs ; SDG 4: Quality Education through workshops and lifelong learning; SDG 5: Gender Equality by creating inclusive spaces and addressing the needs of senior women; SDG 10: Reduced Inequalities by ensuring access for seniors from diverse backgrounds; SDG 11: Sustainable Cities and Communities by building age-friendly, inclusive communities; and SDG 17: Partnerships for the Goals through its collaborative model with public, private, and community partners. Empowering seniors through Accessible Wellness Programs: At the core of 2ND INNINGS is the belief that every elderly individual deserves access to health and happiness. The startup has launched an affordable membership model under its 'I Care, We Care' movement, empowering seniors to live with joy and purpose, while giving families a way to actively support their loved ones. For just AED 49/month or AED 19/month (billed yearly), members can enjoy daily digital fitness sessions, regular online or physical meetups with like-minded seniors, and a warm, supportive community, ensuring vibrant lifestyles, meaningful friendships, and better health without financial stress. Health – Online yoga classes and guided meditation for physical and mental wellbeing, Customized fitness routines are curated to meet seniors where they are—whether they're taking their first steps toward wellness or continuing a lifelong journey. Online meets – adopting the new reality, virtual meetings are set up to introduce senior citizens to each other. Groups are formed basis ethnicities and languages spoken. Where Neighbours Become Friends – Nothing can replace the human touch. Meetup's will be organized around neighbourhoods in which members live for a memorable in person experiences. Board games, quizzes and other fun activities will enhance the pleasure of social contact. 'We believe that the second phase of life can be its most joyful and meaningful chapter. Achieving Ma'an certification during the UAE's Year of Community inspires us to further strengthen our mission and contribute to a more inclusive, age-friendly society,' said Sonam Bhayani, Founder and CEO of 2ND INNINGS. Her husband Yash Bhayani, the social venture's co-founder, shares this ethos and has joined Sonam in the effort. The startup invites seniors, families, corporates, and community partners to engage with its growing platform and help shape a more connected and compassionate future for the UAE's ageing population.

Arabian Post

2 days ago

• Arabian Post

AI‑Powered Phage Therapy Set to Tackle Antibiotic Resistance

Phagos, a Paris‑based biotech startup, is deploying an artificial‑intelligence model built on Amazon Web Services to accurately match bacteriophages with antibiotic‑resistant bacterial strains. This development marks a pivotal shift from arbitrary trial‑and‑error methods to precision medicine in combating infections that claim an estimated one million lives annually. The challenge of antibiotic resistance has spurred Phagos, co‑founded by microbiologist Adèle James and economist Alexandros Pantalis, to pursue alternative therapies. Phages are viruses that specifically infect bacteria, a property that enables targeted treatment without disrupting beneficial microorganisms. But identifying the right phage for a given pathogen has traditionally required labour‑intensive screening of millions of combinations. Phagos is leveraging AWS's Generative AI Accelerator Programme, which has provided them with cloud credits, embedded AWS architects and machine‑learning engineers, and dedicated mentorship, to build a generative AI platform capable of predicting effective pairings between phages and bacterial strains. The AI model has been trained on datasets from public repositories and proprietary lab results. ADVERTISEMENT 'We can now read into the DNA and see if there's going to be an interaction between a phage and a bacterium,' Pantalis explained. This capability bypasses exhaustive wet‑lab testing and accelerates the discovery pipeline. Phagos's strategy involves initial trials in animal health—shrimp, chicken, bovine, swine—with phages administered through water systems to curb infections in farm environments. James noted that reducing antibiotic use in livestock is critical, as drug‑resistant bacteria generated in farms can transfer to humans via environmental pathways. The startup's first validation came from a collaboration with an oyster farmer in France, where AI‑matched phages slashed mortality by 40 per cent. Technical infrastructure from AWS played a crucial role, with cloud experts helping to refine the system and scale it efficiently. 'We became much faster, and spent way less time figuring out how to set up our infrastructure,' James said. Globally, the antibiotic resistance crisis is projected to cause more deaths than cancer by mid‑century, with economic impacts exceeding US$1.5 trillion. By automating phage matching, Phagos aims to create personalised and adaptive therapies that evolve in tandem with bacterial mutations. Participation in AWS's 2024 accelerator—which selected just 80 startups from over 4,700 applicants—has provided Phagos not only with technical and financial support, but also exposure to industry networks and potential funding sources. The platform-as‑a‑service model being developed by Phagos positions the company as a pioneer in AI‑driven microbiological model building. One quarter of its team now focuses exclusively on data and machine learning, a rarity in biotech. Expansion plans are underway: the company intends to move into human therapeutic applications by 2030, while continuing its work in agriculture. It is also advancing bespoke phage therapies, distinguishing itself from generic phage cocktails pursued by competitors. While obstacles remain—such as regulatory pathways for phage-based treatments and the complexity of bacterial ecosystems—Phagos believes its AI model and cloud infrastructure provide a scalable solution. Each new phage cocktail generates data that feeds into the platform, enhancing future predictions.

Dubai Eye

3 days ago

• Dubai Eye

Death toll rises in Gaza as aid-seeking crowds come under fire

Dozens of Palestinians have been killed by Israeli fire in the past two days while trying to access food aid in Gaza, amid a worsening hunger crisis, according to local medics. On Thursday, medics reported at least 51 people killed by Israeli gunfire and airstrikes. Among them were 12 Palestinians who tried to approach a site operated by the US-backed Gaza Humanitarian Foundation (GHF) in the central part of the Strip. The incident is the latest in a string of deadly encounters involving civilians seeking food. The Israeli military said several individuals it described as "suspects" approached its forces near the Netzarim corridor in central Gaza in a way that endangered troops. It said soldiers fired warning shots to deter them and that it was not aware of any injuries at the time. Elsewhere in Gaza on Thursday, medics reported 39 people killed in separate Israeli airstrikes in the north of the territory. One strike on the Shati refugee camp in Gaza City killed at least 19 people, including women and children. Another strike killed at least 14 people in Jabalia and damaged several homes. There was no immediate comment from the Israeli army on those attacks. Gaza's health ministry said hundreds of Palestinians have been killed while trying to reach GHF distribution sites since late May. The United Nations has criticized the GHF's delivery system, calling it inadequate, dangerous and a violation of humanitarian impartiality. Israel defends the system as a necessary safeguard against diversion of aid by Hamas, a claim Hamas denies. GHF said Wednesday it had distributed 3 million meals across three sites in Gaza without incident. The war in Gaza began after Hamas launched a surprise attack on Israel on October 7, 2023, killing 1,200 people and taking 251 hostages, according to Israeli figures. Israel's ongoing military campaign has since killed nearly 55,600 Palestinians, according to Gaza's health ministry, displaced nearly the entire population of over 2 million, and left much of the territory in humanitarian collapse.